Clinical Trial | By Song YB, Gwon HC, Hahn JY et al.
BACKGROUND AND RATIONALE - Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. It is unclear whether P2Y12 inhibitor monotherapy might maintain anti-ischemic efficacy while reducing the bleeding risk c...
Clinical Trial | By Heatley G, Sood P, MOMENTUM 3 Investigators.
Original Research | By Valle JA, Tamez H, Abbott JD et al.
IMPORTANCE - Recent data support percutaneous revascularization as an alternative to coronary artery bypass grafting in unprotected left main (ULM) coronary lesions. However, the relevance of these trials to current practice is unclear, as patterns and outcomes of ULM percutaneous coronary intervention (PCI) in contemporary US clinical practice are not well studied. OBJECTIVE - To define the curren...
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients With Cancer
Clinical Trial | By Khorana AA, Soff GA, CASSINI Investigators.
BACKGROUND - Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS - In this double-blind, randomized trial involving high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism...
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Clinical Trial | By Carrier M, AVERT Investigators.
BACKGROUND - Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophyl...
The Burden of Cardiovascular Diseases Among US States, 1990-2016
| By Global Burden of Cardiovascular Diseases Collaboration.
Original Research | By SW Liu, YC Li; XY Zeng et al.
IMPORTANCE - Cardiovascular disease (CVD) remains the top cause of death in China. To our knowledge, no consistent and comparable assessments of CVD burden have been produced at subnational levels, and little is understood about the spatial patterns and temporal trends of CVD in China. OBJECTIVE - To determine the national and province-level burden of CVD from 1990 to 2016 in China. DESIGN, SETTIN...
Clinical Trial | By Kapur NK, Alkhouli MA, DeMartini TJ et al.
BACKGROUND - In ST-segment-elevation myocardial infarction (STEMI), infarct size correlates directly with heart failure and mortality. Preclinical testing has shown that, in comparison with reperfusion alone, mechanically unloading the left ventricle (LV) before reperfusion reduces infarct size and that 30 minutes of unloading activates a cardioprotective program that limits reperfusion injury. The DTU-STEMI pilot trial ...
Percutaneous Support Devices for Percutaneous Coronary Intervention